Switch to Marcel Bally's research page...

2009

1. Kalra J, Warburton C, Fang K, Edwards L, Daynard T, Waterhouse D, Dragowska W, Sutherland BW, Dedhar S, Gelmon K, Bally M. QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outcomes in an orthotopic breast cancer model. Breast Cancer Res. 11(3):R25. (2009).
    [View Abstract - PubMed 19409087]  Request Paper

2. Musende AG, Eberding A, Wood C, Adomat H, Fazli L, Hurtado-Coll A, Jia W, Bally MB, Guns ET. Pre-clinical evaluation of Rh2 in PC-3 human xenograft model for prostate cancer in vivo: formulation, pharmacokinetics, biodistribution and efficacy. Cancer Chemother Pharmacol. 2009 Mar 20. (2009).
    [View Abstract - PubMed 19301006]  Request Paper

3. Verreault M, Bally MB. siRNA-mediated integrin-linked kinase suppression: nonspecific effects of siRNA/cationic liposome complexes trigger changes in the expression of phosphorylated-AKT and mTOR independently of ILK silencing. Oligonucleotides. 19(2):129-40. (2009).
    [View Abstract - PubMed 19284309]  Request Paper

2008

4. Baker JHE, Lam J, Kyle AH, Sy J, Oliver T, Co S, Dragowska WH, Ramsay E, Anantha M, Ruth TJ, Adam MJ, Yung A, Kozlowski P, Minchinton AI, Ng SSW, Bally MB and Yapp DTT. Irinophore C^TM, A Novel Nano-Formulation of Irinotecan, Alters Tumor Vascular Function, and Enhances the Distribution of 5-FU and Doxorubicin Clin Cancer Res 2008 Nov 15:14(22):7260-7l (2008).
    [View Abstract - PubMed 19010842]  Request Paper

5. Edwards LA, Woo J, Huxam LA, Verreault M, Chiu G, Rajput A, Kyle AH, Karle J, Dragowska WH, Yapp D, Yan H, Minchinton AK, Huntsman D, Daynard T, Waterhouse DN, Thiessen B, Dedhar S and Bally MB. Suppression of VEGF Secretion and Changes in Glioblastoma Mmultiforme Microenvironment by Inhibition of Integrin-Linked Kinase (ILK) Mol Cancer Ther 2008 Jan;7(1):59-70 (2008).
    [View Abstract - PubMed 18202010]  Request Paper

6. McDonald PC, Oloumi A, Mills J, Dobreva I, Maidan M, Gray V, Wederell E, Bally MB, Foster L and Dedhar S . Rictor and Integrin-Linked Kinase Interact and Regulate Akt Phosphorylatin and Cancer Cell Survival Cancer Res 2008;68(6):1618-24 (2008).
    [View Abstract - PubMed 18339839]  Request Paper

7. Qadir MA, Kwok B, Dragowska WH, To KH, Le D, Bally MB and Gorski SM . Macroautophagy Inhibition Sensitizes Tamoxifen-Resistant Breast Cancer Cells and Enhances Mitochondrial Depolarization Breast Cancer Res Treat. 2008 Dec;112(3):389-403. Epub 2008 Jan (2008).
    [View Abstract - PubMed 18172760]  Request Paper

8. Ramsay EC, Anantha M, Zastre J, Meijs M, Zonderhuis J, Strutt D, Webb MS, Waterhouse D and Bally MB. Irinophore CTM : A Liposome Formulation of Irinotecan with Substantially Improved Therapeutic Efficacy Against a Panel of Human Xenograft Tumors Clin Cancer Res. 2008;14(4):1208-17 (2008).
    [View Abstract - PubMed 18281556]  Request Paper

9. Tucker CA, Kapanen AI, Chikh G, Hoffman BG, Kyle AH, Wilson IM, Masin D, Gascoyne RD, Bally M and Klasa RJ . Silencing Bcl-2 in Models of Mantle Cell Lymphoma Correlates with a Loss in Cyclin D1a Expression but not Cyuclin D1b and is Associated with Decreases in NFkappaB, p53, bax and p27 Levels Molecular Cancer Therapy 2008 Apr;7(4):749-58 (2008).
    [View Abstract - PubMed 18375822]  Request Paper

10. Woo J, Chiu GN, Karlsson G, Wasan E, Ickenstein L, Edwards K, Bally MB. Use of a passive equilibration methodology to encapsulate cisplatin into preformed thermosensitive liposomes. Int J Pharm. 349(1-2):38-46. Epub 2007 Jul 24. (2008).
     [View Abstract - PubMed 17728083]  Request Paper

2007

11. Chiu GN, Edwards LA, Kapanen AI, Malinen MM, Dragowska WH, Warburton C, Chikh GG, Fang KY, Tan S, Sy J, Tucker C, Waterhouse DN, Klasa R, Bally MB. Modulation of cancer cell survival pathways using multivalent liposomal therapeutic antibody constructs. Mol Cancer Ther. 6(3):844-55. Epub 2007 Mar 5. (2007).
     [View Abstract - PubMed 17339368]  Request Paper

12. Dos Santos N, Allen C, Doppen AM, Anantha M, Cox KA, Gallagher RC, Karlsson G, Edwards K, Kenner G, Samuels L, Webb MS, Bally MB. Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: Relating plasma circulation lifetimes to protein binding. Biochim Biophys Acta. 1768(6):1367-77. Epub 2007 Jan 3. (2007).
     [View Abstract - PubMed 17400180]  Request Paper

13. Dragowska WH, Verreault M, Yapp DT, Warburton C, Edwards L, Ramsay EC, Huxham LA, Minchinton AI, Gelmon K, Bally MB. Decreased levels of hypoxic cells in gefitinib treated ER(+) HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin. Breast Cancer Res Treat. . (2007).
     [View Abstract - PubMed 17347776]  Request Paper

14. Ponce AM, Viglianti BL, Yu D, Yarmolenko PS, Michelich CR, Woo J, Bally MB, Dewhirst MW. Magnetic resonance imaging of temperature-sensitive liposome release: drug dose painting and antitumor effects. J Natl Cancer Inst. 99(1):53-63. (2007).
     [View Abstract - PubMed 17202113]  Request Paper

15. Ramsay E, Alnajim J, Anantha M, Zastre J, Yan H, Webb M, Waterhouse D and Bally M. A Novel Liposomal Irinotecan Formulation with Significant Anti-tumor Activity: Use of the divalent cation ionophore A23187 and copper-containing liposomes to improve drug retention Eur J Pharm 2008 Mar;68(3):607-17. Epub 2007 Sept 2. (2007).
     Request Paper

16. Tardi PG, Gallagher RC, Johnstone S, Harasym N, Webb M, Bally MB, Mayer LD. Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo. Biochim Biophys Acta. 1768(3):678-87. Epub 2006 Dec 6. (2007).
     [View Abstract - PubMed 17208196]  Request Paper

17. To K, Zhao Y, Jiang H, Hu K, Wang M, Wu J, Lee C, Yokom DW, Stratford AL, Klinge U, Mertens PR, Chen CS, Bally M, Yapp D and Dunn SE . The Phosphoinositide-Dependent Kinase-1 Inhibitor 2-amino-N-[4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1- yl]phenyl]-acetamide (OSU-03012) prevents Y-box binding protein-1 from inducing epidermal growth factor receptor Mol Pharmacol. 2007 Sep;72(3):641-52. Epub 2007 Jun 26. (2007).
     Request Paper

18. Webb MS, Boman N, Masin D, Yapp D, Ramsay E, Chiu GNC, Cullis PR, and Bally MB . A Cationic Liposomal Vincristine Formulation with Improved Vincristine Retention, Extended Circulation Lifetime and Increased Anti-Tumor Activity Letters in Drug Design and Discovery September 2007;4(6):426-433. (2007).
     Request Paper

19. Webb MS, Johnstone S, Morris TJ, Kennedy A, Gallagher R, Harasym N, Harasym T, Shew CR, Tardi P, Dragowska WH, Mayer LD, Bally MB. In vitro and in vivo characterization of a combination chemotherapy formulation consisting of vinorelbine and phosphatidylserine. Eur J Pharm Biopharm. 65(3):289-99. Epub 2006 Oct 17. (2007).
     [View Abstract - PubMed 17123800]  Request Paper

20. Webb MS, Rebstein P, Lamson W and Bally MB . Liposomal Drug Delivery: Recent Patents and Emerging Opportunities Recent Patents on Drug Delivery and Formulation 2007, 1(3) (2007).
     Request Paper

21. Zastre J, Anantha M, Ramsay E, Bally M. Irinotecan-cisplatin interactions assessed in cell-based screening assays: cytotoxicity, drug accumulation and DNA adduct formation in an NSCLC cell line. Cancer Chemother Pharmacol. 60(1):91-102. Epub 2006 Sep 29. (2007).
     [View Abstract - PubMed 17009029]  Request Paper

2006

22. Chiu GNC, Harasym TO, Tardi PG, Bally MB and Waterhouse DN. Optimization and Therapeutic Activity of Liposome-Conjugated Monoclonal Antibodies Against the ErbB Family of Receptor Tyrosin Kinases: First Step in the Development of Therapeutic Antibody/Liposomal anticancer Drug Combinations Letters in Drug Design and Discovery (2006).
     Request Paper

23. Cogswell S, Berger S, Waterhouse D, Bally MB, Wasan EK. A parenteral econazole formulation using a novel micelle-to-liposome transfer method: in vitro characterization and tumor growth delay in a breast cancer xenograft model. Pharm Res. 23(11):2575-85. Epub 2006 Sep 13. (2006).
     [View Abstract - PubMed 17086505]  Request Paper

24. Edwards LA, Verreault M, Thiessen B, Dragowska WH, Hu Y, Yeung JH, Dedhar S, Bally MB. Combined inhibition of the phosphatidylinositol 3-kinase/Akt and Ras/mitogen-activated protein kinase pathways results in synergistic effects in glioblastoma cells. Mol Cancer Ther. 5(3):645-54. (2006).
     [View Abstract - PubMed 16546979]  Request Paper

25. Mayer LD, Harasym TO, Tardi PG, Harasym NL, Shew CR, Johnstone SA, Ramsay EC, Bally MB, Janoff AS. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther. 5(7):1854-63. (2006).
     [View Abstract - PubMed 16891472]  Request Paper

26. Ramsay E, Alnajim J, Anantha M, Taggar A, Thomas A, Edwards K, Karlsson G, Webb M, Bally M. Transition metal-mediated liposomal encapsulation of irinotecan (CPT-11) stabilizes the drug in the therapeutically active lactone conformation. Pharm Res. 23(12):2799-808. Epub 2006 Oct 25. (2006).
     [View Abstract - PubMed 17063397]  Request Paper

27. Taggar AS, Alnajim J, Anantha M, Thomas A, Webb M, Ramsay E, Bally MB. Copper-topotecan complexation mediates drug accumulation into liposomes. J Control Release. 114(1):78-88. Epub 2006 Jun 2. (2006).
     [View Abstract - PubMed 16842880]  Request Paper

28. Troussard AA, McDonald PC, Wederell ED, Mawji NM, Filipenko NR, Gelmon KA, Kucab JE, Dunn SE, Emerman JT, Bally MB, Dedhar S. Preferential dependence of breast cancer cells versus normal cells on integrin-linked kinase for protein kinase B/Akt activation and cell survival. Cancer Res. 66(1):393-403. (2006).
     [View Abstract - PubMed 16397254]  Request Paper

29. Tucker CA, Bebb G, Klasa RJ, Chhanabhai M, Lestou V, Horsman DE, Gascoyne RD, Wiestner A, Masin D, Bally M, Williams ME. Four human t(11;14)(q13;q32)-containing cell lines having classic and variant features of Mantle Cell Lymphoma. Leuk Res. 30(4):449-57. Epub 2005 Sep 23. (2006).
     [View Abstract - PubMed 16183118]  Request Paper

30. Verreault M, Webb MS, Ramsay EC, Bally MB. Gene silencing in the development of personalized cancer treatment: the targets, the agents and the delivery systems. Curr Gene Ther. 6(4):505-33. (2006).
     [View Abstract - PubMed 16918337]  Request Paper

31. Viglianti BL, Ponce AM, Michelich CR, Yu D, Abraham SA, Sanders L, Yarmolenko PS, Schroeder T, MacFall JR, Barboriak DP, Colvin OM, Bally MB, Dewhirst MW. Chemodosimetry of in vivo tumor liposomal drug concentration using MRI. Magn Reson Med. 56(5):1011-8. (2006).
     [View Abstract - PubMed 17029236]  Request Paper

32. Waterhouse DN, Gelmon KA, Klasa R, Chi K, Huntsman D, Ramsay E, Wasan E, Edwards L, Tucker C, Zastre J, Wang YZ, Yapp D, Dragowska W, Dunn S, Dedhar S, Bally MB. Development and assessment of conventional and targeted drug combinations for use in the treatment of aggressive breast cancers. Curr Cancer Drug Targets. 6(6):455-89. (2006).
     [View Abstract - PubMed 17017873]  Request Paper

2005

33. Abraham SA, Waterhouse DN, Mayer LD, Cullis PR, Madden TD, Bally MB. The liposomal formulation of doxorubicin. Methods Enzymol. 391:71-97. (2005).
     [View Abstract - PubMed 15721375]  Request Paper

34. Chiu GN, Abraham SA, Ickenstein LM, Ng R, Karlsson G, Edwards K, Wasan EK, Bally MB. Encapsulation of doxorubicin into thermosensitive liposomes via complexation with the transition metal manganese. J Control Release. 104(2):271-88. Epub 2005 Apr 13. (2005).
     [View Abstract - PubMed 15907579]  Request Paper

35. Dos Santos N, Waterhouse D, Masin D, Tardi PG, Karlsson G, Edwards K, Bally MB. Substantial increases in idarubicin plasma concentration by liposome encapsulation mediates improved antitumor activity. J Control Release. 105(1-2):89-105. (2005).
     [View Abstract - PubMed 15878792]  Request Paper

36. Edwards LA, Thiessen B, Dragowska WH, Daynard T, Bally MB, Dedhar S. Inhibition of ILK in PTEN-mutant human glioblastomas inhibits PKB/Akt activation, induces apoptosis, and delays tumor growth. Oncogene. 24(22):3596-605. (2005).
     [View Abstract - PubMed 15782140]  Request Paper

37. Edwards LA, Thiessen B, Dragowska WH, Daynard T, Bally MB, Dedhar S. Inhibition of ILK in PTEN-mutant human glioblastomas inhibits PKB/Akt activation, induces apoptosis, and delays tumor growth. Oncogene . (2005).
     [View Abstract - PubMed 15782140]  Request Paper

38. Ramsay EC, Dos Santos N, Dragowska WH, Laskin JJ, Bally MB. The formulation of lipid-based nanotechnologies for the delivery of fixed dose anticancer drug combinations. Curr Drug Deliv. 2(4):341-51. (2005).
     [View Abstract - PubMed 16305437]  Request Paper

39. Waterhouse DN, Denyssevych T, Hudon N, Chia S, Gelmon KA, Bally MB. Trastuzumab and liposomal Doxorubicin in the treatment of mcf-7 xenograft tumor-bearing mice: combination does not affect drug serum levels. Pharm Res. 22(6):915-22. Epub 2005 Jun 8. (2005).
     [View Abstract - PubMed 15948035]  Request Paper

2004

40. Abraham SA, Edwards K, Karlsson G, Hudon N, Mayer LD, Bally MB. An evaluation of transmembrane ion gradient-mediated encapsulation of topotecan within liposomes. J Control Release 96(3):449-61. (2004).
     [View Abstract - PubMed 15120901]  Request Paper

41. Abraham SA, McKenzie C, Masin D, Ng R, Harasym TO, Mayer LD, Bally MB. In vitro and in vivo characterization of doxorubicin and vincristine coencapsulated within liposomes through use of transition metal ion complexation and pH gradient loading. Clin Cancer Res 10(2):728-38. (2004).
     [View Abstract - PubMed 14760096]  Request Paper

42. Dos Santos N, Cox KA, McKenzie CA, van Baarda F, Gallagher RC, Karlsson G, Edwards K, Mayer LD, Allen C, Bally MB. pH gradient loading of anthracyclines into cholesterol-free liposomes: enhancing drug loading rates through use of ethanol. Biochim Biophys Acta 1661(1):47-60. (2004).
     [View Abstract - PubMed 14967474]  Request Paper

43. Dragowska WH, Warburton C, Yapp DT, Minchinton AI, Hu Y, Waterhouse DN, Gelmon K, Skov K, Woo J, Masin D, Huxham LA, Kyle AH, Bally MB. HER-2/neu Overexpression Increases the Viable Hypoxic Cell Population within Solid Tumors without Causing Changes in Tumor Vascularization. Mol Cancer Res 2(11):606-19. (2004).
     [View Abstract - PubMed 15561777]  Request Paper

44. Hu Y, Bebb G, Tan S, Ng R, Yan H, Sartor JR, Mayer LD, Bally MB. Antitumor efficacy of oblimersen Bcl-2 antisense oligonucleotide alone and in combination with vinorelbine in xenograft models of human non-small cell lung cancer. Clin Cancer Res 10(22):7662-70. (2004).
     [View Abstract - PubMed 15569999]  Request Paper

45. Hu Y, Krishan A, Nie W, Sridhar KS, Mayer LD, Bally M. Synergistic cytotoxicity of pyrazoloacridine with Doxorubicin, Etoposide, and topotecan in drug-resistant tumor cells. Clin Cancer Res 10(3):1160-9. (2004).
     [View Abstract - PubMed 14871996]  Request Paper

46. Messerer CL, Ramsay EC, Waterhouse D, Ng R, Simms EM, Harasym N, Tardi P, Mayer LD, Bally MB. Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer. Clin Cancer Res 10(19):6638-49. (2004).
     [View Abstract - PubMed 15475454]  Request Paper

47. Schutze-Redelmeier MP, Kong S, Bally MB, Dutz JP. Antennapedia transduction sequence promotes anti tumour immunity to epicutaneously administered CTL epitopes. Vaccine 22(15-16):1985-91. (2004).
     [View Abstract - PubMed 15121311]  Request Paper

48. Viglianti BL, Abraham SA, Michelich CR, Yarmolenko PS, MacFall JR, Bally MB, Dewhirst MW. In vivo monitoring of tissue pharmacokinetics of liposome/drug using MRI: Illustration of targeted delivery. Magn Reson Med 51(6):1153-62. (2004).
     [View Abstract - PubMed 15170835]  Request Paper

49. Warburton C, Dragowska WH, Gelmon K, Chia S, Yan H, Masin D, Denyssevych T, Wallis AE, Bally MB. Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction. Clin Cancer Res 10(7):2512-24. (2004).
     [View Abstract - PubMed 15073131]  Request Paper

50. Waterhouse DN, Dragowska WH, Gelmon KA, Mayer LD, Bally MB. Pharmacodynamic Behavior of Liposomal Antisense Oligonucleotides Targeting Her-2/neu and Vascular Endothelial Growth Factor in an Ascitic MDA435/LCC6 Human Breast Cancer Model. Cancer Biol Ther 3(2):1-8 (2004).
     [View Abstract - PubMed 14726684]  Request Paper

2003

51. Chiu GN, Bally MB, Mayer LD. Targeting of antibody conjugated, phosphatidylserine-containing liposomes to vascular cell adhesion molecule 1 for controlled thrombogenesis. Biochim Biophys Acta 1613(1-2):115-21. (2003).
     [View Abstract - PubMed 12832092]  Request Paper

52. Hu Y, Bally M, Dragowska WH, Mayer L. Inhibition of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase enhances chemotherapeutic effects on H460 human non-small cell lung cancer cells through activation of apoptosis. Mol Cancer Ther 2(7):641-9. (2003).
     [View Abstract - PubMed 12883037]  Request Paper

53. Li WM, Dragowska WH, Bally MB, Schutze-Redelmeier MP. Effective induction of CD8+ T-cell response using CpG oligodeoxynucleotides and HER-2/neu-derived peptide co-encapsulated in liposomes. Vaccine 21(23):3319-29. (2003).
     [View Abstract - PubMed 12804863]  Request Paper

54. Waterhouse DN, Gelmon KA, Masin D, Bally MB. Combining doxorubicin and liposomal anti-HER-2/NEU antisense oligodeoxynucleotides to treat HER-2/NEU-expressing MDA-MB-435 breast tumor model. J Exp Ther Oncol 3(5):261-71. (2003).
     [View Abstract - PubMed 14696623]  Request Paper

55. Wong FM, Harvie P, Zhang YP, Ramsay EC, Bally MB. Phosphatidylethanolamine mediated destabilization of lipid-based pDNA delivery systems. Int J Pharm 255(1-2):117-27. (2003).
     [View Abstract - PubMed 12672608]  Request Paper

2002

56. Abraham S, Edwards K, Karlsson G, MacIntosh S, Mayer L, McKenzie C, Bally M. Formation of transition metal-doxorubicin complexes inside liposomes. Biochim Biophys Acta 1565(1):41. (2002).
     [View Abstract - PubMed 12225851]  Request Paper

57. Allen C, Dos Santos N, Gallagher R, Chiu GN, Shu Y, Li WM, Johnstone SA, Janoff AS, Mayer LD, Webb MS, Bally MB. Controlling the physical behavior and biological performance of liposome formulations through use of surface grafted poly(ethylene glycol). Biosci Rep 22(2):225-50. (2002).
     [View Abstract - PubMed 12428902]  Request Paper

58. Chikh GG, Li WM, Schutze-Redelmeier MP, Meunier JC, Bally MB. Attaching histidine-tagged peptides and proteins to lipid-based carriers through use of metal-ion-chelating lipids. Biochim Biophys Acta 1567(1):204-12. (2002).
     [View Abstract - PubMed 12488054]  Request Paper

59. Chiu GN, Bally MB, Mayer LD. Effects of phosphatidylserine on membrane incorporation and surface protection properties of exchangeable poly(ethylene glycol)-conjugated lipids. Biochim Biophys Acta 1560(1-2):37-50. (2002).
     [View Abstract - PubMed 11958774]  Request Paper

60. Dos Santos N, Mayer LD, Abraham SA, Gallagher RC, Cox KA, Tardi PG, Bally MB. Improved retention of idarubicin after intravenous injection obtained for cholesterol-free liposomes. Biochim Biophys Acta 1561(2):188-201. (2002).
     [View Abstract - PubMed 11997119]  Request Paper

61. Edwards LA, Woo J, Huxam LA, Verreault M, Chiu G, Rajput A, Kyle AH, Karle J, Dragowska WH, Yapp D, Yan H, Minchinton AK, Huntsman D, Daynard T, Waterhouse DN, Thiessen B, Dedhar S and Bally MB . Suppression of VEGF Secretion and Changes in Glioblastoma Mmultiforme Microenvironment by Inhibition of Integrin-Linked Kinase (ILK) Mol Cancer Ther 2008 Jan;7(1):59-70 (2002).
     [View Abstract - PubMed 18202010]  Request Paper

62. Guns ES, Denyssevych T, Dixon R, Bally MB, Mayer L. Drug interaction studies between paclitaxel (Taxol) and OC144-093--a new modulator of MDR in cancer chemotherapy. Eur J Drug Metab Pharmacokinet 27(2):119-26. (2002).
     [View Abstract - PubMed 12064370]  Request Paper

63. Hu Q, Bally MB, Madden TD. Subcellular trafficking of antisense oligonucleotides and down-regulation of bcl-2 gene expression in human melanoma cells using a fusogenic liposome delivery system. Nucleic Acids Res 30(16):3632-41. (2002).
     [View Abstract - PubMed 12177306]  Request Paper

64. Li WM, Mayer LD, Bally MB. Prevention of antibody-mediated elimination of ligand-targeted liposomes by using poly(ethylene glycol)-modified lipids. J Pharmacol Exp Ther 300(3):976-83. (2002).
     [View Abstract - PubMed 11861806]  Request Paper

65. Wasan EK, Waterhouse D, Sivak O, Bally MB, Klasa RJ, Wasan KM. Plasma protein binding, lipoprotein distribution and uptake of free and lipid-associated BCL-2 antisense oligodeoxynucleotides (G3139) in human melanoma cells. Int J Pharm 241(1):57-64. (2002).
     [View Abstract - PubMed 12086721]  Request Paper

66. Wong FMP, Macadam SA, Kim A, Oja C, Ramsay EC and Bally MB. A Lipid-Based Delivery System for Antisense Oligonucleotides Derived from a Hydrophobic Complex. J. of Drug Targeting 10(8):615-623 (2002).
     [View Abstract - PubMed 12683666]  Request Paper

2001

67. Chikh G, Bally M, Schutze-Redelmeier MP. Characterization of hybrid CTL epitope delivery systems consisting of the Antennapedia homeodomain peptide vector formulated in liposomes. J Immunol Methods 254(1-2):119-35. (2001).
     [View Abstract - PubMed 11406158]  Request Paper

68. Chikh GG, Kong S, Bally MB, Meunier JC, Schutze-Redelmeier MP. Efficient delivery of Antennapedia homeodomain fused to CTL epitope with liposomes into dendritic cells results in the activation of CD8+ T cells. J Immunol 167(11):6462-70. (2001).
     [View Abstract - PubMed 11714813]  Request Paper

69. Chiu GN, Bally MB, Mayer LD. Selective protein interactions with phosphatidylserine containing liposomes alter the steric stabilization properties of poly(ethylene glycol). Biochim Biophys Acta 1510(1-2):56-69. (2001).
     [View Abstract - PubMed 11342147]  Request Paper

70. Guns ES, Bullock PL, Reimer ML, Dixon R, Bally M, Mayer LD. Assessment of the involvement of CYP3A in the vitro metabolism of a new modulator of MDR in cancer chemotherapy, OC144-193, by human liver microsomes. Eur J Drug Metab Pharmacokinet 26(4):273-82. (2001).
     [View Abstract - PubMed 11808870]  Request Paper

71. Hu Q, Shew CR, Bally MB, Madden TD. Programmable fusogenic vesicles for intracellular delivery of antisense oligodeoxynucleotides: enhanced cellular uptake and biological effects. Biochim Biophys Acta 1514(1):1-13. (2001).
     [View Abstract - PubMed 11513800]  Request Paper

72. Johnstone SA, Masin D, Mayer L, Bally MB. Surface-associated serum proteins inhibit the uptake of phosphatidylserine and poly(ethylene glycol) liposomes by mouse macrophages. Biochim Biophys Acta 1513(1):25-37. (2001).
     [View Abstract - PubMed 11427191]  Request Paper

73. Li WM, Bally MB, Schutze-Redelmeier MP. Enhanced immune response to T-independent antigen by using CpG oligodeoxynucleotides encapsulated in liposomes. Vaccine 20(1-2):148-57. (2001).
     [View Abstract - PubMed 11567759]  Request Paper

74. Li WM, Xue L, Mayer LD, Bally MB. Intermembrane transfer of polyethylene glycol-modified phosphatidylethanolamine as a means to reveal surface-associated binding ligands on liposomes. Biochim Biophys Acta 1513(2):193-206. (2001).
     [View Abstract - PubMed 11470091]  Request Paper

75. Waterhouse D N, Tardi P G, Mayer L D, Bally M B. A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles. Drug Saf 24(12):903-20. (2001).
     [View Abstract - PubMed 11735647]  Request Paper

76. Waterhouse DN, Dos Santos N, Mayer LD, Bally MB. Drug-drug interactions arising from the use of liposomal vincristine in combination with other anticancer drugs. Pharm Res 18(9):1331-5. (2001).
     [View Abstract - PubMed 11683249]  Request Paper

77. Wong M, Kong S, Dragowska WH, Bally MB. Oxazole yellow homodimer YOYO-1-labeled DNA: a fluorescent complex that can be used to assess structural changes in DNA following formation and cellular delivery of cationic lipid DNA complexes. Biochim Biophys Acta 1527(1-2):61-72. (2001).
     [View Abstract - PubMed 11420144]  Request Paper

2000

78. Dos Santos N, Cox KA, McKenzie CA, van Baarda F, Gallagher RC, Karlsson G, Edwards K, Mayer LD, Allen C and Bally MB. pH Gradient Loading of Anthracyclines into Cholesterol-Free Liposomes: Enchancing Drug Loading Rates Through Use of Ethanol Biochim Biophys Acta. 1661:47-60. (2000).
     Request Paper

79. Harvie P, Wong FM, Bally MB. Use of poly(ethylene glycol)-lipid conjugates to regulate the surface attributes and transfection activity of lipid-DNA particles. J Pharm Sci 89(5):652-63. (2000).
     [View Abstract - PubMed 10756331]  Request Paper

80. Johnstone SA, Gelmon K, Mayer LD, Hancock RE, Bally MB. In vitro characterization of the anticancer activity of membrane-active cationic peptides. I. Peptide-mediated cytotoxicity and peptide-enhanced cytotoxic activity of doxorubicin against wild-type and p-glycoprotein over-expressing tumor cell lines. Anticancer Drug Des 15(2):151-60. (2000).
     [View Abstract - PubMed 10901303]  Request Paper

81. Klasa RJ, Bally MB, Ng R, Goldie JH, Gascoyne RD, Wong FM. Eradication of human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide. Clin Cancer Res 6(6):2492-500. (2000).
     [View Abstract - PubMed 10873104]  Request Paper

82. Lim HJ, Masin D, McIntosh NL, Madden TD, Bally MB. Role of drug release and liposome-mediated drug delivery in governing the therapeutic activity of liposomal mitoxantrone used to treat human A431 and LS180 solid tumors. J Pharmacol Exp Ther 292(1):337-45. (2000).
     [View Abstract - PubMed 10604968]  Request Paper

83. Lim HJ, Parr MJ, Masin D, McIntosh NL, Madden TD, Zhang G, Johnstone S, Bally MB. Kupffer cells do not play a role in governing the efficacy of liposomal mitoxantrone used to treat a tumor model designed to assess drug delivery to liver. Clin Cancer Res 6(11):4449-60. (2000).
     [View Abstract - PubMed 11106266]  Request Paper

84. Mayer LD, Krishna R, Webb M and Bally MB. Designing Liposomal Anticancer Drug Formulations for Specific Therapeutic Applications J. Liposome Res., 10(2-3):99-115. (2000).
     Request Paper

85. Saxon D, Chia SK and Bally MB . Drug Combinations for Therapy of Aggressive Breast Cancer: Antisense Oligonucleotides Against HER-2/NEU Biological Therapy of Breast Cancer, 1(3):7-11. (2000).
     Request Paper

86. Tardi P, Choice E, Masin D, Redelmeier T, Bally M, Madden TD. Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models. Cancer Res 60(13):3389-93. (2000).
     [View Abstract - PubMed 10910044]  Request Paper

1999

87. Adlakha-Hutcheon G, Bally MB, Shew CR, Madden TD. Controlled destabilization of a liposomal drug delivery system enhances mitoxantrone antitumor activity. Nat Biotechnol 17(8):775-9. (1999).
     [View Abstract - PubMed 10429242]  Request Paper

88. Bally MB, Harvie P, Wong FM, Kong S, Wasan EK, Reimer DL. Biological barriers to cellular delivery of lipid-based DNA carriers. Adv Drug Deliv Rev 38(3):291-315. (1999).
     [View Abstract - PubMed 10837762]  Request Paper

89. Gelmon KA, Tolcher A, Diab AR, Bally MB, Embree L, Hudon N, Dedhar C, Ayers D, Eisen A, Melosky B, Burge C, Logan P, Mayer LD. Phase I study of liposomal vincristine. J Clin Oncol 17(2):697-705. (1999).
     [View Abstract - PubMed 10080616]  Request Paper

90. Mayer LD, Reamer J, Bally MB. Intravenous pretreatment with empty pH gradient liposomes alters the pharmacokinetics and toxicity of doxorubicin through in vivo active drug encapsulation. J Pharm Sci 88(1):96-102. (1999).
     [View Abstract - PubMed 9874708]  Request Paper

91. Reimer DL, Kong S, Monck M, Wyles J, Tam P, Wasan EK, Bally MB. Liposomal lipid and plasmid DNA delivery to B16/BL6 tumors after intraperitoneal administration of cationic liposome DNA aggregates. J Pharmacol Exp Ther 289(2):807-15. (1999).
     [View Abstract - PubMed 10215656]  Request Paper

92. Saxon DN, Mayer LD and Bally MB . Liposomal Anticancer Drugs as Agents to be Used in Combination with Other Anticancer Agents: Studies on a Liposomal Formulation with Two Encapsulated Drugs J. Liposome Res., 9:507-522. (1999).
     Request Paper

93. Wasan EK, Harvie P, Edwards K, Karlsson G, Bally MB. A multi-step lipid mixing assay to model structural changes in cationic lipoplexes used for in vitro transfection. Biochim Biophys Acta 1461(1):27-46. (1999).
     [View Abstract - PubMed 10556486]  Request Paper

94. Wong FM, Bally MB, Brooks DE. Electrostatically mediated interactions between cationic lipid-DNA particles and an anionic surface. Arch Biochem Biophys 366(1):31-9. (1999).
     [View Abstract - PubMed 10334860]  Request Paper

1998

95. Bally MB, Lim H, Cullis PR and Mayer LD . Controlling the Drug Delivery Attributes of Lipid-Based Drug Formulations J. Liposome Res. 8(3):299-335. (1998).
     Request Paper

96. Embree L, Gelmon K, Tolcher A, Hudon N, Heggie J, Dedhar C, Logan P, Bally MB, Mayer LD. Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection. Cancer Chemother Pharmacol 41(5):347-52. (1998).
     [View Abstract - PubMed 9523729]  Request Paper

97. Harvie P, Wong FM, Bally MB, Harvie P, Wong FM, Bally MB. Characterization of lipid DNA interactions. I. Destabilization of bound lipids and DNA dissociation. Biophys J 75(2):1040-51. (1998).
     [View Abstract - PubMed 9675205]  Request Paper

98. Tardi P, Bally MB, Harasym TO. Clearance properties of liposomes involving conjugated proteins for targeting. Adv Drug Deliv Rev 32(1-2):99-118. (1998).
     [View Abstract - PubMed 10837638]  Request Paper

99. Wasan EK, Fairchild A, Bally MB. Cationic liposome--plasmid DNA complexes used for gene transfer retain a significant trapped volume. J Pharm Sci 87(1):9-14. (1998).
     [View Abstract - PubMed 9452961]  Request Paper

100. Webb MS, Logan P, Kanter PM, St-Onge G, Gelmon K, Harasym T, Mayer LD, Bally MB. Preclinical pharmacology, toxicology and efficacy of sphingomyelin/cholesterol liposomal vincristine for therapeutic treatment of cancer. Cancer Chemother Pharmacol 42(6):461-70. (1998).
      [View Abstract - PubMed 9788572]  Request Paper

101. Webb MS, Saxon D, Wong FM, Lim HJ, Wang Z, Bally MB, Choi LS, Cullis PR, Mayer LD. Comparison of different hydrophobic anchors conjugated to poly(ethylene glycol): effects on the pharmacokinetics of liposomal vincristine. Biochim Biophys Acta 1372(2):272-82. (1998).
      [View Abstract - PubMed 9675310]  Request Paper

1997

102. Bally MB, Ansell SM, Tardi PG and Harasym TO. Liposome Targeting Following Intravenous Administration: Defining Expectations and a Need for Improved Methodology J. Liposome Res. 7(4):331-361. (1997).
      Request Paper

103. Bally MB, Zhang Y-P, Wong FMP, Kong S, Wasan E and Reimer DL . Lipid/DNA Complexes as an Intermediate in the Preparation of Particles for Gene Transfer: An Alternative to Cationic Liposome/DNA Aggregates Advanced Drug Delivery Reviews, 24(2-3):275-290. (1997).
      Request Paper

104. Chang CW, Barber L, Ouyang C, Masin D, Bally MB, Madden TD. Plasma clearance, biodistribution and therapeutic properties of mitoxantrone encapsulated in conventional and sterically stabilized liposomes after intravenous administration in BDF1 mice. Br J Cancer 75(2):169-77. (1997).
      [View Abstract - PubMed 9010021]  Request Paper

105. Cullis PR, Hope MJ, Bally MB, Madden TD, Mayer LD, Fenske DB. Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and metal ions into large unilamellar vesicles. Biochim Biophys Acta 1331(2):187-211. (1997).
      [View Abstract - PubMed 9325441]  Request Paper

106. Embree L, Gelmon KA, Tolcher AW, Hudon NJ, Heggie JR, Dedhar C, Webb MS, Bally MB, Mayer LD. Validation of a high-performance liquid chromatographic assay method for quantification of total vincristine sulfate in human plasma following administration of vincristine sulfate liposome injection. J Pharm Biomed Anal 16(4):675-87. (1997).
      [View Abstract - PubMed 9502163]  Request Paper

107. Harasym TO, Cullis PR, Bally MB. Intratumor distribution of doxorubicin following i.v. administration of drug encapsulated in egg phosphatidylcholine/cholesterol liposomes. Cancer Chemother Pharmacol 40(4):309-17. (1997).
      [View Abstract - PubMed 9225948]  Request Paper

108. Lim HJ, Masin D, Madden TD, Bally MB. Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone. J Pharmacol Exp Ther 281(1):566-73. (1997).
      [View Abstract - PubMed 9103545]  Request Paper

109. Mayer LD, Dougherty G, Harasym TO, Bally MB. The role of tumor-associated macrophages in the delivery of liposomal doxorubicin to solid murine fibrosarcoma tumors. J Pharmacol Exp Ther 280(3):1406-14. (1997).
      [View Abstract - PubMed 9067330]  Request Paper

110. Parr MJ, Masin D, Cullis PR, Bally MB. Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol). J Pharmacol Exp Ther 280(3):1319-27. (1997).
      [View Abstract - PubMed 9067319]  Request Paper

111. Reimer DL, Bally MB and Singh SM . Human gene therapy: Principles and modern advances Biotechnology Ann. Rev., 1997, 3:59-110. (1997).
      Request Paper

112. Reimer DL, Kong S, Bally MB. Analysis of cationic liposome-mediated interactions of plasmid DNA with murine and human melanoma cells in vitro. J Biol Chem 272(31):19480-7. (1997).
      [View Abstract - PubMed 9235950]  Request Paper

113. Tardi PG, Swartz EN, Harasym TO, Cullis PR, Bally MB. An immune response to ovalbumin covalently coupled to liposomes is prevented when the liposomes used contain doxorubicin. J Immunol Methods 210(2):137-48. (1997).
      [View Abstract - PubMed 9520297]  Request Paper

114. Zhang YP, Reimer DL, Zhang G, Lee PH, Bally MB. Self-assembling DNA-lipid particles for gene transfer. Pharm Res 14(2):190-6. (1997).
      [View Abstract - PubMed 9090708]  Request Paper

1996

115. Boman NL, Tron VA, Bally MB, Cullis PR. Vincristine-induced dermal toxicity is significantly reduced when the drug is given in liposomes. Cancer Chemother Pharmacol 37(4):351-5. (1996).
      [View Abstract - PubMed 8548881]  Request Paper

116. Silver HKB, Klasa RJ and Bally MB . Genetic Allogenization of Malignant Melanoma Transfus. Sci., 17(1):169-174. (1996).
      Request Paper

117. Wasan EK, Reimer DL, Bally MB. Plasmid DNA is protected against ultrasonic cavitation-induced damage when complexed to cationic liposomes. J Pharm Sci 85(4):427-33. (1996).
      [View Abstract - PubMed 8901083]  Request Paper

118. Wong FM, Reimer DL, Bally MB. Cationic lipid binding to DNA: characterization of complex formation. Biochemistry 35(18):5756-63. (1996).
      [View Abstract - PubMed 8639536]  Request Paper

1995

119. Boman NL, Bally MB, Cullis PR, Mayer LD and Webb MS . Encapsulation of Vincristine in Liposomes Reduces Its Toxicity and Improves Its Anti-Tumor Efficacy J. Liposome Res., 5:523-541. (1995).
      Request Paper

120. Choice E, Masin D, Bally MB, Meloche M, Madden TD. Liposomal cyclosporine. Comparison of drug and lipid carrier pharmacokinetics and biodistribution. Transplantation 60(9):1006-11. (1995).
      [View Abstract - PubMed 7491673]  Request Paper

121. De Jong G, Gelmon K, Bally M, Goldie J, Mayer L. Modulation of doxorubicin resistance in P388/ADR cells by Ro44-5912, a tiapamil derivative. Anticancer Res 15(3):911-6. (1995).
      [View Abstract - PubMed 7645981]  Request Paper

122. Harasym TO, Tardi P, Longman SA, Ansell SM, Bally MB, Cullis PR, Choi LS. Poly(ethylene glycol)-modified phospholipids prevent aggregation during covalent conjugation of proteins to liposomes. Bioconjug Chem 6(2):187-94. (1995).
      [View Abstract - PubMed 7599262]  Request Paper

123. Longman SA, Cullis PR and Bally MB . A Model Approach for Assessing Liposome Targeting in vivo Drug Delivery, 2:156-165. (1995).
      Request Paper

124. Longman SA, Cullis PR, Choi L, de Jong G, Bally MB. A two-step targeting approach for delivery of doxorubicin-loaded liposomes to tumour cells in vivo. Cancer Chemother Pharmacol 36(2):91-101. (1995).
      [View Abstract - PubMed 7767956]  Request Paper

125. Longman SA, Tardi PG, Parr MJ, Choi L, Cullis PR, Bally MB. Accumulation of protein-coated liposomes in an extravascular site: influence of increasing carrier circulation lifetimes. J Pharmacol Exp Ther 275(3):1177-84. (1995).
      [View Abstract - PubMed 8531079]  Request Paper

126. Mayer LD, Gelmon K, Cullis PR, Boman N, Webb MS, Embree L, Tolcher T and Bally MB. Preclinical and Clinical Studies With Liposomal Vincristine In: Progress in Drug Delivery System, Vol. 4, pp. 151-161, Biomedical Research Foundation, Tokyo. (1995).
      Request Paper

127. Mayer LD, Masin D, Nayar R, Boman NL, Bally MB. Pharmacology of liposomal vincristine in mice bearing L1210 ascitic and B16/BL6 solid tumours. Br J Cancer 71(3):482-8. (1995).
      [View Abstract - PubMed 7880728]  Request Paper

128. Redelmeier TE, Guillet J-G and Bally MB . High Affinity Targeting of Biotin Labeled Liposomes to Streptavidin Conjugated Ligands Drug Delivery. 2:98-109. (1995).
      Request Paper

129. Reimer DL, Zhang Y, Kong S, Wheeler JJ, Graham RW, Bally MB. Formation of novel hydrophobic complexes between cationic lipids and plasmid DNA. Biochemistry 34(39):12877-83. (1995).
      [View Abstract - PubMed 7548044]  Request Paper

130. Webb MS, Harasym TO, Masin D, Bally MB, Mayer LD. Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br J Cancer 72(4):896-904. (1995).
      [View Abstract - PubMed 7547237]  Request Paper

131. Webb MS, Wheeler JJ, Bally MB, Mayer LD. The cationic lipid stearylamine reduces the permeability of the cationic drugs verapamil and prochlorperazine to lipid bilayers: implications for drug delivery. Biochim Biophys Acta 1238(2):147-55. (1995).
      [View Abstract - PubMed 7548129]  Request Paper

1994

132. Bally MB, Masin D, Nayar R, Cullis PR, Mayer LD. Transfer of liposomal drug carriers from the blood to the peritoneal cavity of normal and ascitic tumor-bearing mice. Cancer Chemother Pharmacol 34(2):137-46. (1994).
      [View Abstract - PubMed 8194164]  Request Paper

133. Boman NL, Masin D, Mayer LD, Cullis PR, Bally MB. Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors. Cancer Res 54(11):2830-3. (1994).
      [View Abstract - PubMed 8187061]  Request Paper

134. Kanter PM, Klaich GM, Bullard GA, King JM, Bally MB, Mayer LD. Liposome encapsulated vincristine: preclinical toxicologic and pharmacologic comparison with free vincristine and empty liposomes in mice, rats and dogs. Anticancer Drugs 5(5):579-90. (1994).
      [View Abstract - PubMed 7858291]  Request Paper

135. Mayer LD, Cullis PR and Bally MB . The Use of Transmembrane pH Liposomal Doxorubicin Liposome Res., 4:529-553. (1994).
      Request Paper

136. Wheeler JJ, Wong KF, Ansell SM, Masin D, Bally MB. Polyethylene glycol modified phospholipids stabilize emulsions prepared from triacylglycerol. J Pharm Sci 83(11):1558-64. (1994).
      [View Abstract - PubMed 7891274]  Request Paper

1993

137. Mayer LD, Nayar R, Thies RL, Boman NL, Cullis PR, Bally MB. Identification of vesicle properties that enhance the antitumour activity of liposomal vincristine against murine L1210 leukemia. Cancer Chemother Pharmacol 33(1):17-24. (1993).
      [View Abstract - PubMed 8269584]  Request Paper

138. Parr MJ, Bally MB, Cullis PR. The presence of GM1 in liposomes with entrapped doxorubicin does not prevent RES blockade. Biochim Biophys Acta 1168(2):249-52. (1993).
      [View Abstract - PubMed 8504161]  Request Paper

1991

139. Cullis PR, Bally MB, Madden TD, Mayer LD, Hope MJ. pH gradients and membrane transport in liposomal systems. Trends Biotechnol 9(8):268-72. (1991).
      [View Abstract - PubMed 1367566]  Request Paper

1990

140. Bally MB, Nayar R, Masin D, Cullis PR, Mayer LD. Studies on the myelosuppressive activity of doxorubicin entrapped in liposomes. Cancer Chemother Pharmacol 27(1):13-9. (1990).
      [View Abstract - PubMed 2245488]  Request Paper

141. Bally MB, Nayar R, Masin D, Hope MJ, Cullis PR, Mayer LD. Liposomes with entrapped doxorubicin exhibit extended blood residence times. Biochim Biophys Acta 1023(1):133-9. (1990).
      [View Abstract - PubMed 2317492]  Request Paper

142. Loughrey HC, Bally MB, Reinish LW, Cullis PR. The binding of phosphatidylglycerol liposomes to rat platelets is mediated by complement. Thromb Haemost 64(1):172-6. (1990).
      [View Abstract - PubMed 2274922]  Request Paper

143. Loughrey HC, Choi LS, Cullis PR, Bally MB. Optimized procedures for the coupling of proteins to liposomes. J Immunol Methods 132(1):25-35. (1990).
      [View Abstract - PubMed 2391438]  Request Paper

144. Loughrey HC, Wong KF, Choi LS, Cullis PR, Bally MB. Protein-liposome conjugates with defined size distributions. Biochim Biophys Acta 1028(1):73-81. (1990).
      [View Abstract - PubMed 2207121]  Request Paper

145. Madden TD, Harrigan PR, Tai LC, Bally MB, Mayer LD, Redelmeier TE, Loughrey HC, Tilcock CP, Reinish LW, Cullis PR. The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: a survey. Chem Phys Lipids 53(1):37-46. (1990).
      [View Abstract - PubMed 1972352]  Request Paper

146. Mayer LD, Bally MB and Cullis PR . Strategies for Optimizing Liposomal Doxorubicin J. Liposome Res. 1:463-480. (1990).
      Request Paper

147. Mayer LD, Bally MB, Cullis PR, Wilson SL, Emerman JT. Comparison of free and liposome encapsulated doxorubicin tumor drug uptake and antitumor efficacy in the SC115 murine mammary tumor. Cancer Lett 53(2-3):183-90. (1990).
      [View Abstract - PubMed 2208078]  Request Paper

148. Mayer LD, Bally MB, Loughrey H, Masin D, Cullis PR. Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors. Cancer Res 50(3):575-9. (1990).
      [View Abstract - PubMed 2297698]  Request Paper

149. Mayer LD, Tai LC, Bally MB, Mitilenes GN, Ginsberg RS, Cullis PR. Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients. Biochim Biophys Acta 1025(2):143-51. (1990).
      [View Abstract - PubMed 2364073]  Request Paper

150. Thies RL, Cowens DW, Cullis PR, Bally MB, Mayer LD. Method for rapid separation of liposome-associated doxorubicin from free doxorubicin in plasma. Anal Biochem 188(1):65-71. (1990).
      [View Abstract - PubMed 2221370]  Request Paper

1989

151. Balazsovits JA, Mayer LD, Bally MB, Cullis PR, McDonell M, Ginsberg RS, Falk RE. Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin. Cancer Chemother Pharmacol 23(2):81-6. (1989).
      [View Abstract - PubMed 2491964]  Request Paper

152. Cullis PR, Mayer LD, Bally MB, Madden TD and Hope MJ. Generation and Loading of Liposomal Systems for Drug Delivery Application Advanced Drug Delivery Review 3:267-282. (1989).
      Request Paper

153. Doerschuk CM, Gie RP, Bally MB, Cullis PR, Reinish LW. Platelet distribution in rabbits following infusion of liposomes. Thromb Haemost 61(3):392-6. (1989).
      [View Abstract - PubMed 2799754]  Request Paper

154. Mayer LD, Tai LC, Ko DS, Masin D, Ginsberg RS, Cullis PR, Bally MB. Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. Cancer Res 49(21):5922-30. (1989).
      [View Abstract - PubMed 2790807]  Request Paper

155. Redelmeier TE, Mayer LD, Wong KF, Bally MB, Cullis PR, Redelmeier TE, Mayer LD, Wong KF, Bally MB, Cullis PR. Proton flux in large unilamellar vesicles in response to membrane potentials and pH gradients. Biophys J 56(2):385-93. (1989).
      [View Abstract - PubMed 2775833]  Request Paper

1988

156. Bally MB, Mayer LD, Loughrey H, Redelmeier T, Madden TD, Wong K, Harrigan PR, Hope MJ, Cullis PR. Dopamine accumulation in large unilamellar vesicle systems induced by transmembrane ion gradients. Chem Phys Lipids 47(2):97-107. (1988).
      [View Abstract - PubMed 2457454]  Request Paper

157. Reinish LW, Bally MB, Loughrey HC, Cullis PR. Interactions of liposomes and platelets. Thromb Haemost 60(3):518-23. (1988).
      [View Abstract - PubMed 3238654]  Request Paper

1987

158. Loughrey H, Bally MB, Cullis PR. A non-covalent method of attaching antibodies to liposomes. Biochim Biophys Acta 901(1):157-60. (1987).
      [View Abstract - PubMed 3593723]  Request Paper

1986

159. Hope MJ, Bally MB, Mayer LD, Janoff AS and Cullis PR. Generation of Multilamellar and Unilamellar Phospholipid Vesicles Chem. Phys. Lipids 40:89-108. (1986).
      Request Paper

160. Mayer LD, Bally MB, Cullis PR. Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient. Biochim Biophys Acta 857(1):123-6. (1986).
      [View Abstract - PubMed 3964703]  Request Paper

161. Mayer LD, Bally MB, Hope MJ, Cullis PR. Techniques for encapsulating bioactive agents into liposomes. Chem Phys Lipids 40(2-4):333-45. (1986).
      [View Abstract - PubMed 3742676]  Request Paper

1985

162. Bally MB, Hope MJ, van Echteld CJA and Cullis PR . Uptake of Safranine and Other Lipophilic Cations into Vesicles in Response to a Membrane Potential Biochim. Biophys. Acta 812:66-76. (1985).
      Request Paper

163. Hope MJ, Bally MB, Webb G and Cullis PR . Production of Large Unilamellar Vesicles by a Rapid Extrusion Procedure: Characterization of Size, Trapped Volume and Ability to Maintain a Membrane Potential Biochim. Biophys. Acta 812:55-65. (1985).
      Request Paper

164. Madden TD, Bally MB, Hope MJ, Cullis PR, Schieren HP, Janoff AS. Protection of large unilamellar vesicles by trehalose during dehydration: retention of vesicle contents. Biochim Biophys Acta 817(1):67-74. (1985).
      [View Abstract - PubMed 4005259]  Request Paper

165. Mayer LD, Bally MB, Hope MJ, Cullis PR. Uptake of antineoplastic agents into large unilamellar vesicles in response to a membrane potential. Biochim Biophys Acta 816(2):294-302. (1985).
      [View Abstract - PubMed 3839135]  Request Paper

166. Mayer LD, Bally MB, Hope MJ, Cullis PR. Uptake of dibucaine into large unilamellar vesicles in response to a membrane potential. J Biol Chem 260(2):802-8. (1985).
      [View Abstract - PubMed 3968068]  Request Paper

167. Shertzer HG, Bally MB, Opheim DJ. Inhibition of alveolar macrophage killing by di(2-ethylhexyl)phthalate. Arch Environ Contam Toxicol 14(5):605-8. (1985).
      [View Abstract - PubMed 4051570]  Request Paper

168. Thomas P, Bally MB and Neff JM . Influence of Some Environmental Variables on the Ascorbic Acid Status of Mullet (Mugil Cephalus Linn.) Tissues II. Seasonal Fluctuations and Biosynthetic Ability J. Fish Biol. 27:47-57. (1985).
      Request Paper

1984

169. Tilcock CP, Bally MB, Farren SB, Cullis PR, Gruner SM. Cation-dependent segregation phenomena and phase behavior in model membrane systems containing phosphatidylserine: influence of cholesterol and acyl chain composition. Biochemistry 23(12):2696-703. (1984).
      [View Abstract - PubMed 6466608]  Request Paper

1983

170. Bally MB, Tilcock CP, Hope MJ, Cullis PR. Polymorphism of phosphatidylethanolamine-phosphatidylserine model systems: influence of cholesterol and Mg2+ on Ca2+-triggered bilayer to hexagonal (HII) transitions. Can J Biochem Cell Biol 61(6):346-52. (1983).
      [View Abstract - PubMed 6883167]  Request Paper

171. Carr RS, Bally MB, Thomas P, Neff JM. Comparison of methods for determination of ascorbic acid in animal tissues. Anal Chem 55(8):1229-32. (1983).
      [View Abstract - PubMed 6614490]  Request Paper

1982

172. Thomas P, Bally MB and Neff JM . Ascorbic Acid Status of Mullet Exposed to Cadmium J. Fish Biology 20:183-186. (1982).
      Request Paper

173. Tilcock CP, Bally MB, Farren SB, Cullis PR, Tilcock CP, Bally MB, Farren SB, Cullis PR. Influence of cholesterol on the structural preferences of dioleoylphosphatidylethanolamine-dioleoylphosphatidylcholine systems: a phosphorus-31 and deuterium nuclear magnetic resonance study. Biochemistry 21(19):4596-601. (1982).
      [View Abstract - PubMed 7138819]  Request Paper

1980

174. Bally MB, Opheim DJ, Shertzer HG. Di-(2-ethylhexyl) phthalate enhances the release of lysosomal enzymes from alveolar macrophages during phagocytosis. Toxicology 18(1):49-60. (1980).
      [View Abstract - PubMed 7210023]  Request Paper

2004

1. Bally MB, Tardi P, Harasym T, Harasym N, Swenson C, Janoff A and Mayer LD. "Spotlight Celator Technologies" Controlled Release Society Newsletter, vol.21, number 2, 2004 (2004).
    Request Paper

2005

1. Ramsay EC, Dos Santos N, Dragowska WH, Laskin JJ, Bally MB. The formulation of lipid-based nanotechnologies for the delivery of fixed dose anticancer drug combinations. Curr Drug Deliv. 2(4):341-51. (2005).
    [View Abstract - PubMed 16305437]  Request Paper

2004

2. Edwards LA, Shabbits JA, Bally M, Dedhar S. Integrin-linked kinase (ILK) in combination molecular targeting. Cancer Treat Res 119:59-75. (2004).
    [View Abstract - PubMed 15164873]  Request Paper

2008

1. Waterhouse DN, Kalra J, Verreault M, Ramsay E, Dragowska W, Yapp D, Webb M, Chiu G and Bally MB . Nanotechnology as an Enabling Approach to the Development of Fixed-Dose Combination Products for Treating Cancer In: Handbook of Particulate Drug Delivery, Vol.2: Applications, pp.11-39 (M.N.V. Ravi Kumar, Ed), American Scientific Publishers (2008).
    Request Paper

2006

2. Harasym TO, Tardi PG, Johnstone SA, Mayer LD, Bally MB and Janoff AS. Fixed Drug Ratio Liposome Formulations of Combination Cancer Therapeutics Liposome Technology Third Edition, Vol. III, Interactions of Liposomes with the Biological Milieu, pp.25-48 (G. Gregoriadis, Ed), Informa Healthcare USA, Inc. (2006).
    Request Paper

2005

3. Abraham SA, Waterhouse DN, Mayer L, Cullis P, Madden T and Bally MB. Liposomal Formulations of Doxorubicin In: Methods in Enzymology, Vol.391, Liposomes, Part E, pp.71-97 (N. Duzgunes, Ed), Elsevier Academic Press (2005).
    [View Abstract - PubMed 15721375]  Request Paper

4. Waterhouse DN, Bally MB, Mayer LD, Madden TD, Cullis PR and Webb MS. Preparation, Characterization and Biological Analysis of Liposomal Formulations of Vincristine n: Methods in Enzymology, Vol.391, Liposomes, Part E, pp.40-57 (N. Duzgunes, Ed), Elsevier Academic Press (2005).
    [View Abstract - PubMed 15721373]  Request Paper

2001

5. Mayer LD, Krishna R and Bally, MB . Liposomes for Cancer Therapy Applications In: Polymeric Biomaterials, 2nd Edition (S. Dumitriu, ed.) Marcel Dekker (New York, NY), 823-841. (2001).
    Request Paper

6. Tardi P, Ickenstein L, Bally M and Mayer LD . The Development of Liposomes for Enhanced Delivery of Chemotherpeutics to Tumors In: Cancer Drug Discovery and Development: Tumor Targeting in Cancer Therapy, pp. 119-135 (M. Page, Ed), Humana Press Inc., Totowa, NJ. (2001).
    Request Paper

2000

7. Ansell SM, Harasym TO, Tardi PG, Buchkowsky SS, Bally MB and Cullis PR. Antibody Conjugation Methods for Active Targeting of Lipsomes In: Methods in Molecular Medicine, Vol. 25: Drug Targeting: Strategies, Principles, and Applications, pp. 51-68 (G.E. Francis and C. Delgado, Ed.), Humana Press Inc., Totowa, NJ. (2000).
    Request Paper

8. Wasan EK, Reimer DL, Harvie P, Kong S, Wong FMP and Bally MB . Targeted Gene Transfer: A Practical Guide Based on Experience with Lipid-Based Plasmid Delivery Systems In: Methods in Molecular Medicine, Vol. 25: Drug Targeting: Strategies, Principles, and Applications, pp. 255-304 (G.E. Francis and C. Delgado, Ed.), Humana Press Inc., Totowa, NJ. (2000).
    Request Paper

1998

9. Mayer LD, Cullis PR and Bally MB . Designing Therapeutically Optimized Liposomal Anticancer Delivery Systems: Lessons from Conventional Liposomes In: Medical Applications of Liposomes, DD Lasic and D Papahadjopoulos, eds., Elsevier, N.Y., pp. 231-257. (1998).
    Request Paper

1997

10. Boman NL, Cullis PR, Mayer LD, Bally MB and Webb MS . Liposomal Vincristine: The Central Role of Drug Retention in Defining Therapeutically Optimized Anticancer Formulations In: Long Circulating Liposomes: Old Drugs, New Therapeutics, 29-49. (1997).
     Request Paper

1995

11. Boman NL, Cullis PR, Bally MB and Mayer LD . Preclinical and Clinical Activity of Liposomal Doxorubicin In: Liposomes in Biomedical Applications, (PN Shek, Ed.), 85-103. (1995).
     Request Paper

1993

12. Bally MB, Mayer LD, Hope MJ and Nayar R . Pharmacodynamics of Liposomal Drug Carriers: Methodological Considerations In: Liposome Technology: 2nd Edition, (G Gregoriadis, Ed.), Vol. 3, Pp. 27-42, CRC Press, Inc., Boca Raton, FL. (1993).
     Request Paper

13. Loughrey HC, Choi LS, Wong KF, Cullis PR and Bally MB . Preparation of Streptavidin Liposomes for use in Ligand Specific Targeting Applications In: Liposome Technology: 2nd Edition, (G Gregoriadis, Ed.), Vol. 3, Pp. 163-178, CRC Press, Inc., Boca Raton, FL. (1993).
     Request Paper

14. Mayer LD, Bally MB, Madden TD and Cullis PR . Transmembrane pH Gradient Driven Drug Loading Procedure In: Liposome Technology: 2nd Edition, (G Gregoriadis, Ed.), Vol. 2, Pp. 27-44, CRC Press, Inc., Boca Raton, FL. (1993).
     Request Paper

1988

15. Bally MB, Hope MJ, Mayer LD, Madden TD and Cullis PR . Novel Procedures for Generating and Loading Liposomal Systems In: Liposomes As Drug Carriers: Recent Trends and Progress, (G Gregoriadis, Ed.), John Wiley and Sons, New York, Pp. 841-853. (1988).
     Request Paper

1987

16. Cullis PR, Hope MJ, Bally MB, Janoff AS, Madden TD and Mayer LD . Liposomes As Pharmaceuticals In: Liposomes, (M Ostro, Ed.), Marcel Dekker, New York, Pp. 39-72. (1987).
     Request Paper

1982

17. Cullis PR, De Kruiff B, Hope MJ, Verkleij AJ, Nayar R, Farren SB, Tilcock CPS, Madden TD and Bally MB . Structural Properties of Lipids and Their Functional Roles in Biological Membranes In: Membrane Fluidity, Volume 2, (RC Aloia, Ed.), Academic Press, New York, Pp. 39-81. (1982).
     Request Paper